Article Versions Notes

Mulder EEAP, Johansson I, Grünhagen DJ, Tempel D, Rentroia-Pacheco B, Dwarkasing JT, Verver D, Mooyaart AL, van der Veldt AAM, Wakkee M, et al. Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I–II Melanoma Patients at Risk of Disease Relapse. Cancers. 2022; 14(12):2854. https://doi.org/10.3390/cancers14122854

Mulder, Evalyn E. A. P., Iva Johansson, Dirk J. Grünhagen, Dennie Tempel, Barbara Rentroia-Pacheco, Jvalini T. Dwarkasing, Daniëlle Verver, Antien L. Mooyaart, Astrid A. M. van der Veldt, Marlies Wakkee, and et al. 2022. "Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I–II Melanoma Patients at Risk of Disease Relapse" Cancers 14, no. 12: 2854. https://doi.org/10.3390/cancers14122854

Mulder, E. E. A. P., Johansson, I., Grünhagen, D. J., Tempel, D., Rentroia-Pacheco, B., Dwarkasing, J. T., Verver, D., Mooyaart, A. L., van der Veldt, A. A. M., Wakkee, M., Nijsten, T. E. C., Verhoef, C., Mattsson, J., Ny, L., Hollestein, L. M., & Olofsson Bagge, R. (2022). Using a Clinicopathologic and Gene Expression (CP-GEP) Model to Identify Stage I–II Melanoma Patients at Risk of Disease Relapse. Cancers, 14(12), 2854. https://doi.org/10.3390/cancers14122854